Safety and Clinical Outcomes With Amniotic and Umbilical Cord Tissue Therapy for Numerous Medical Conditions
Launched by R3 STEM CELL · Mar 29, 2019
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating the safety and effectiveness of using amniotic and umbilical cord tissue to treat a variety of medical conditions, including issues related to bones and joints (like arthritis), the nervous system (like Alzheimer's and Parkinson's diseases), kidney problems, heart conditions, and lung diseases. The researchers hope that this treatment will not only be safe but also improve patients' quality of life.
To participate in the trial, individuals must be at least 18 years old and able to attend follow-up visits or communicate through phone or email. They should have specific conditions, such as arthritis, chronic kidney disease, or certain heart problems, among others. However, people with active cancer, those who are pregnant or breastfeeding, or individuals with severe bleeding disorders cannot take part. Participants will have regular check-ins to monitor their health and assess how well the treatment is working. The trial is currently not recruiting, so interested individuals should stay tuned for updates.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age 18 and over.
- • 2. Ability to attend follow up visits or at least converse on phone or complete email follow up forms.
- • 3. Competent to understand the study protocol and provide voluntary informed consent.
- • 4. Patients with any of the following conditions: Arthritis (Degenerative, Rheumatoid, Psoriatic, Lupus, Gout), Sports or Overuse Injuries (e.g. Rotator Cuff injury, Tennis Elbow), Chronic Kidney Disease (may be on dialysis), Back/Neck Pain, Erectile Dysfunction, Peyronie's Disease, Alzheimer's Disease, Parkinson's Disease, Neuropathy, Post-Stroke, Post-Concussion Syndrome, COPD, Emphysema, Pulmonary Fibrosis, Post myocardial infarction (at least 6 months out), Cardiomyopathy, Congestive Heart Failure.
- Exclusion Criteria:
- • 1. Active Cancer
- • 2. Pregnancy, Lactating
- • 3. Severe Clotting disorder
- • 4. Myocardial Infarction less than six months ago.
About R3 Stem Cell
r3 stem cell is a leading clinical trial sponsor specializing in advanced regenerative medicine and stem cell therapies. Committed to innovative research and patient-centered solutions, r3 stem cell focuses on developing safe and effective treatments for a range of degenerative conditions. With a robust portfolio of clinical trials, the organization collaborates with healthcare professionals and regulatory bodies to ensure adherence to the highest standards of clinical practice and ethical guidelines. By leveraging cutting-edge technology and scientific expertise, r3 stem cell aims to transform the landscape of medical treatments and improve patient outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
David Greene, MD, MBA
Study Director
R3 Stem Cell
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials